I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| glutamatergic neuron | 3 studies | 34% ± 6% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| glutamatergic neuron | 3 studies | 34% ± 6% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 3 studies | 26% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 100% | 44.07 | 244 / 245 | 71% | 1.26 | 358 / 502 |
| thymus | 99% | 35.91 | 648 / 653 | 51% | 0.90 | 309 / 605 |
| esophagus | 100% | 57.05 | 1439 / 1445 | 30% | 0.62 | 54 / 183 |
| breast | 97% | 32.40 | 443 / 459 | 32% | 0.63 | 358 / 1118 |
| lung | 95% | 21.62 | 548 / 578 | 26% | 0.86 | 299 / 1155 |
| uterus | 100% | 52.86 | 170 / 170 | 18% | 0.42 | 81 / 459 |
| kidney | 97% | 36.06 | 86 / 89 | 16% | 0.38 | 142 / 901 |
| skin | 90% | 22.72 | 1628 / 1809 | 19% | 0.55 | 88 / 472 |
| pancreas | 97% | 45.42 | 318 / 328 | 11% | 0.19 | 20 / 178 |
| stomach | 99% | 52.08 | 355 / 359 | 8% | 0.25 | 24 / 286 |
| adrenal gland | 99% | 32.28 | 255 / 258 | 7% | 0.13 | 16 / 230 |
| bladder | 95% | 31.71 | 20 / 21 | 10% | 0.28 | 49 / 504 |
| intestine | 93% | 35.61 | 900 / 966 | 12% | 0.24 | 62 / 527 |
| ovary | 100% | 49.31 | 180 / 180 | 3% | 0.05 | 13 / 430 |
| adipose | 97% | 30.57 | 1166 / 1204 | 0% | 0 | 0 / 0 |
| muscle | 94% | 23.34 | 757 / 803 | 0% | 0 | 0 / 0 |
| blood vessel | 94% | 32.43 | 1256 / 1335 | 0% | 0 | 0 / 0 |
| brain | 71% | 13.74 | 1869 / 2642 | 19% | 0.30 | 131 / 705 |
| heart | 88% | 27.15 | 757 / 861 | 0% | 0 | 0 / 0 |
| liver | 55% | 7.24 | 124 / 226 | 4% | 0.10 | 16 / 406 |
| spleen | 50% | 6.73 | 121 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 22% | 0.39 | 10 / 45 |
| peripheral blood | 19% | 3.82 | 175 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 10% | 0.15 | 8 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 3% | 0.04 | 1 / 29 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006554 | Biological process | lysine catabolic process |
| GO_1990550 | Biological process | mitochondrial alpha-ketoglutarate transmembrane transport |
| GO_0006869 | Biological process | lipid transport |
| GO_0005743 | Cellular component | mitochondrial inner membrane |
| GO_0015139 | Molecular function | alpha-ketoglutarate transmembrane transporter activity |
| GO_0015297 | Molecular function | antiporter activity |
| Gene name | SLC25A21 |
| Protein name | Mitochondrial 2-oxodicarboxylate carrier (ODC) (Mitochondrial 2-oxoadipate carrier) (Solute carrier family 25 member 21) |
| Synonyms | ODC |
| Description | FUNCTION: Transports dicarboxylates across the inner membranes of mitochondria by a counter-exchange mechanism . Can transport 2-oxoadipate (2-oxohexanedioate), 2-oxoglutarate, adipate (hexanedioate), glutarate, and to a lesser extent, pimelate (heptanedioate), 2-oxopimelate (2-oxoheptanedioate), 2-aminoadipate (2-aminohexanedioate), oxaloacetate, and citrate . Plays a central role in catabolism of lysine, hydroxylysine, and tryptophan, by transporting common metabolite intermediates (such as 2-oxoadipate) into the mitochondria, where it is converted into acetyl-CoA and can enter the citric acid (TCA) cycle (Probable). . |
| Accessions | ENST00000331299.6 [Q9BQT8-1] ENST00000555449.5 [Q9BQT8-2] Q9BQT8 |
